Maker of an implantable neurostimulation device (Inspire) that treats obstructive sleep apnea by stimulating the airway.
Maker of an implantable neurostimulation device (Inspire) that treats obstructive sleep apnea by stimulating the airway.
Sold per implant to hospitals and surgery centres, where surgeons place the pulse generator and nerve lead, so revenue follows the number of procedures, which depend on insurer approval of each patient. Sleep doctors refer patients who cannot tolerate CPAP masks, and the company trains surgeons and runs patient-marketing campaigns to feed the pipeline.
Moat: narrow (IP / patents, regulatory licence, switching costs). First and only FDA-approved implantable neurostimulator for OSA, with surgeon training lock-in.
Headquarters: Golden Valley, Minnesota · Founded: 2007 · Employees: 1,333
Size Inspire Medical Systems (INSP) is a United States Health Care company (Medical Specialties) with a market value of $1.68B, the 1887th largest of 3,085 United States companies the cockpit tracks. Shares closed at $58.11 on 18 Nov 2026.
Performance Over six months the shares gained 31.6%, against -2.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 0.2% over the last twelve months (peer median +9.4%); the operating margin is 1.8% (peer median 13.6%).
Valuation It trades at 41.3× forward earnings against a peer median of 21.1× (3rd most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +51%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.0 points below its cost of capital (8.4% WACC).
Short interest Short interest is 14.3% of the free float (30 Oct 2026).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $881M | $912M | $803M | $625M | $408M |
| Revenue growth | — | +14% | +28% | +53% | — |
| Gross profit | $759M | $779M | $680M | $528M | $342M |
| EBITDA | $34.4M | $64.9M | $42.6M | -$37.4M | -$44.7M |
| Net income | $101M | $145M | $53.5M | -$21.2M | -$44.9M |
| Free cash flow | $97.9M | $78.5M | $91.1M | $1.02M | $2.47M |
| Capital expenditure | $37.1M | $38.5M | $39.1M | $23.6M | $9.10M |
| Total debt | $28.6M | $32.2M | $31.8M | $24.8M | $8.87M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Inspire Medical Systems INSP | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% |
| ResMed RMD | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% |
| Koninklijke Philips PHIA.AS | $29.0B | +17% | -1% | 10% | 16.4× | 5.9% |
| LivaNova LIVN | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INSP | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.5% | -4.6% | 2nd lowest of 21 |
| 6-month return | +31.6% | -2.3% | 4th highest of 21 |
| Distance from 52-week high | -60.5% | -24.8% | 3rd lowest of 21 |
| Revenue growth (TTM) | -0.2% | +9.4% | 3rd lowest of 21 |
| Operating margin | 1.8% | 13.6% | 3rd lowest of 21 |
| Forward P/E | 41.3× | 21.1× | 3rd most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 28.7% | 11.2% | most demanding of 16 |
| Growth delivered (Del g) | +51.2% | +12.7% | highest of 16 |
| Hurdle (Req g minus delivered) | -22.5 pp | -0.6 pp | least demanding of 16 |
| ROIC minus cost of capital | -6.0 pp | +0.9 pp | 4th lowest of 21 |
| Net debt / EBITDA | -8.7× | -0.8× | least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |